Skip to main content

Lidocaine Hydrochloride and Hydrocortisone Acetate

Generic: Lidocaine Hydrochloride and Hydrocortisone Acetate

Verified·Apr 23, 2026
Manufacturer
Sandoz
NDC
69367-397
RxCUI
1012235
Route
TOPICAL
ICD-10 indication
I84.9

Affordability Check

How much will you actually pay for Lidocaine Hydrochloride and Hydrocortisone Acetate?

In 30 seconds, see every legitimate way to afford Lidocaine Hydrochloride and Hydrocortisone Acetate — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Lidocaine Hydrochloride and Hydrocortisone Acetate

What is this medication? Lidocaine hydrochloride and hydrocortisone acetate is a combination prescription medication used primarily to relieve discomfort associated with inflammatory conditions of the rectal or anal area. Lidocaine functions as a local anesthetic that numbs the skin and surrounding tissues by blocking nerve signals, providing rapid relief from pain and soreness. Hydrocortisone is a corticosteroid that works by reducing inflammation, which helps to decrease swelling, redness, and persistent itching in the affected region. This medication is most frequently prescribed to treat symptoms caused by hemorrhoids, anal fissures, or proctitis. By combining a numbing agent with an anti-inflammatory steroid, the treatment addresses both the immediate sensation of pain and the underlying irritation that causes long-term discomfort. It is typically available in various topical forms, such as creams, gels, or suppositories, and should be used exactly as directed by a healthcare provider to ensure safety and effectiveness.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Lidocaine Hydrochloride and Hydrocortisone Acetate. Official source: DailyMed (NLM) · Label effective Nov 21, 2024

Indications and usage
INDICATIONS Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area.
Dosage and administration
DOSAGE AND ADMINISTRATION Apply product to the affected area(s) twice daily or as directed by a physician. Product should not be used in excess of recommendations or for prolonged used in the anal canal. If the condition does not respond to repeated courses of product or should worsen, discontinue use and seek the advise of your physician. Products without applicators Remove the child-resistant cap and foil seal from the tube. Apply a thin film to the affected area. Replace the cap after use.
Contraindications
CONTRAINDICATIONS Product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with "caine" ester type anesthetics. If excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. Product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. Product should be used with caution in patients receiving antiarrhythmic drugs of Class I since the adverse effects are additive and generally synergistic. Product is contraindicated for tuberculous or fungal lesions of skin vaccinia, varicella and acute herpes simplex. Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any components of the preparation.
Warnings
WARNINGS For external use only. Not for ophthalmic use. Product could harm small children if chewed or swallowed. Keep out of reach of children. Topical formulations of lidocaine may be absorbed to a greater extent through mucous membranes and abraded, fissured or irritated skin than through intact skin. Product should not be ingested or applied into the mouth, inside of the nose or in the eyes. Product should not be used in the ears. Any situation where lidocaine penetrates beyond the tympanic membrane into the middle ear is contraindicted because of ototoxicty associated with lidocaine observed in animals when instilled in the middle ear. Product should not come into contact with the eye or be applied into the eye because of the risk of severe eye irritation and the loss of eye surface sensation, which reduces protective reflexes and can lead to corneal irritation and possibly abrasion. If eye contact occurs, rinse out the eye immediately with saline or water and protect the eye surface until sensation is restored.
Adverse reactions
ADVERSE REACTIONS During or immediately following application of product, there may be transient stinging or burning from open areas of skin, or transient blanching (lightening), or erythema (redness) of the skin.
Use in pregnancy
USE IN PREGNANCY Teratogenic Effects Pregnancy Category C Reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts or for prolonged periods of time.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.